ISAB Stock Overview
Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Inhalation Sciences Sweden AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr4.34 |
| 52 Week High | kr4.99 |
| 52 Week Low | kr2.43 |
| Beta | 0.52 |
| 1 Month Change | 0% |
| 3 Month Change | 3.58% |
| 1 Year Change | 24.36% |
| 3 Year Change | -54.60% |
| 5 Year Change | -42.13% |
| Change since IPO | -53.08% |
Recent News & Updates
Shareholder Returns
| ISAB | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 0.9% |
| 1Y | 24.4% | 7.0% | 10.3% |
Return vs Industry: ISAB exceeded the Swedish Life Sciences industry which returned 11.1% over the past year.
Return vs Market: ISAB exceeded the Swedish Market which returned 10.7% over the past year.
Price Volatility
| ISAB volatility | |
|---|---|
| ISAB Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ISAB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ISAB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 8 | Manoush Masarrat | www.inhalation.se |
Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research. The company’s products portfolio includes PreciseInhale, a laboratory system that allows scientists to measure how inhaled particles act in lungs and affect the health; DissolvIt, which enables in vitro simulation of dissolution and absorption of respirable particles in the lung epithelium; XposeALI, a 3D cell exposure module that combines aerosol capability with 3D cell models cultured at an air liquid interface; Nose-only inhalation, a standard method of exposure used in preclinical testing of inhalation drugs, as well as for inhalation toxicity studies in rodents; and intratracheal exposure module, an unique technology delivering aerosol directly to the lungs, bypassing the nose, and to spontaneously breathing rodents. Inhalation Sciences Sweden AB (publ) was founded in 2004 and is headquartered in Huddinge, Sweden.
Inhalation Sciences Sweden AB (publ) Fundamentals Summary
| ISAB fundamental statistics | |
|---|---|
| Market cap | kr65.83m |
| Earnings (TTM) | -kr4.74m |
| Revenue (TTM) | kr17.50m |
3.8x
P/S Ratio-13.9x
P/E RatioIs ISAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISAB income statement (TTM) | |
|---|---|
| Revenue | kr17.50m |
| Cost of Revenue | kr3.54m |
| Gross Profit | kr13.96m |
| Other Expenses | kr18.71m |
| Earnings | -kr4.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 79.77% |
| Net Profit Margin | -27.10% |
| Debt/Equity Ratio | 8.4% |
How did ISAB perform over the long term?
See historical performance and comparison